Bayer Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 2/6

Bayer hat ein Gesamteigenkapital von €35.8B und eine Gesamtverschuldung von €46.3B, wodurch sich der Verschuldungsgrad auf 129.4% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen €119.9B bzw. €84.1B. Bayer Das EBIT des Unternehmens beträgt €7.9B, so dass der Zinsdeckungsgrad 10.7 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von €4.7B.

Wichtige Informationen

129.4%

Verhältnis von Schulden zu Eigenkapital

€46.27b

Verschuldung

Zinsdeckungsgrad	10.7x
Bargeld	€4.73b
Eigenkapital	€35.76b
Gesamtverbindlichkeiten	€84.12b
Gesamtvermögen	€119.88b

Jüngste Berichte zur Finanzlage

Recent updates

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

Jun 11

The Market Doesn't Like What It Sees From Bayer Aktiengesellschaft's (ETR:BAYN) Revenues Yet

May 07

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt In A Risky Way

Jan 18

Are Investors Undervaluing Bayer Aktiengesellschaft (ETR:BAYN) By 42%?

Dec 27

Bayer (ETR:BAYN) Takes On Some Risk With Its Use Of Debt

Oct 15

Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Be 45% Below Their Intrinsic Value Estimate

Aug 05

Is Bayer (ETR:BAYN) A Risky Investment?

Jun 28

Bayer (ETR:BAYN) Use Of Debt Could Be Considered Risky

Dec 07

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: BAYNDie kurzfristigen Aktiva des Unternehmens (€40.2B) übersteigen seine kurzfristigen Passiva (€30.6B).

Langfristige Verbindlichkeiten: BAYNDie kurzfristigen Vermögenswerte des Unternehmens (€40.2B) decken seine langfristigen Verbindlichkeiten (€53.5B) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: BAYNDie Nettoverschuldung im Verhältnis zum Eigenkapital (116.2%) wird als hoch angesehen.

Schulden abbauen: BAYNDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 84.8% auf 129.4% gestiegen.

Schuldendeckung: BAYNDie Schulden des Unternehmens sind nicht ausreichend durch den operativen Cashflow (14.1%) gedeckt.

Zinsdeckung: BAYNDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (10.7x Coverage) gut gedeckt.

Bayer Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt In A Risky Way

Bayer (ETR:BAYN) Takes On Some Risk With Its Use Of Debt

Is Bayer (ETR:BAYN) A Risky Investment?

Bayer (ETR:BAYN) Use Of Debt Could Be Considered Risky

Recent updates

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

The Market Doesn't Like What It Sees From Bayer Aktiengesellschaft's (ETR:BAYN) Revenues Yet

Upcoming dividend of €0.11 per share

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Price target decreased by 7.7% to €42.48

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Dividend of €0.11 announced

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt In A Risky Way

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Are Investors Undervaluing Bayer Aktiengesellschaft (ETR:BAYN) By 42%?

Williams Hart & Boundas Wins Against Bayer

Price target decreased by 7.7% to €51.57

Price target decreased by 7.6% to €57.57

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Provides Update on Aliqopa (Copanlisib)

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 13%

Bayer Announces Pharmacodynamic Data on Kerendia

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Bayer (ETR:BAYN) Takes On Some Risk With Its Use Of Debt

Bayer to Present Latest Real-World Evidence of Menopausal Symptoms and Their Treatment

Bayer Aktiengesellschaft (XTRA:BAYN) signed an agreement to acquire strawberry pipeline and commercial portfolio from NIAB.

Bayer AG and BlueRock Therapeutics LP Announces Details of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (BRT-DA01), A Stem Cell Derived Investigational Therapy for Treating Parkinson's Disease

Bayer AG and Bluerock Therapeutics LP Announces Results of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (Brt-Da01)

Bayer AG Announces Management Changes

Consensus EPS estimates fall by 11%

New minor risk - Profit margin trend

Second quarter 2023 earnings released: €1.92 loss per share (vs €0.30 loss in 2Q 2022)

Consensus EPS estimates fall by 12%

Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Be 45% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 24%

Bayer Aktiengesellschaft Provides Earnings Guidance for Full-Year 2023

Industrias Químicas del Valles S.A. reached an agreement to acquire Bayer's phytosanitary products factory in Valencia from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Initiates Phase III Studies with Investigational Compound Agent Gadoquatrane

Is Bayer (ETR:BAYN) A Risky Investment?

FDA Approves Bayer's Ultravist® (iopromide) Injection for contrast-enhanced Mammography

Bayer to Investigate Finerenone in Phase Iii Study in Adults with Chronic Kidney Disease Associated with Type 1 Diabetes

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Upcoming dividend of €2.40 per share at 4.0% yield

Consensus EPS estimates fall by 10%

Full year 2022 earnings: EPS misses analyst expectations

Bayer Aktiengesellschaft (XTRA:BAYN) completed the acquisition of Blackford Analysis Ltd.

Bayer AG Announces CEO Changes

Inclusive Capital Partners Provides Information to Shareholders of Bayer Aktiengesellschaft

Union Investment Criticizes Bayer AG Chairman for Lack of Engagement

Bayer Aktiengesellschaft (XTRA:BAYN) agreed to acquire Blackford Analysis Ltd.

Bayer Aktiengesellschaft to Report Q2, 2023 Results on Aug 08, 2023

Bayer (ETR:BAYN) Use Of Debt Could Be Considered Risky

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen